# Vancomycin for Primary Sclerosing Cholangitis

> **NCT03710122** · PHASE2,PHASE3 · TERMINATED · sponsor: **Elizabeth Carey** · enrollment: 102 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Vancomycin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03710122
- **Lead sponsor:** Elizabeth Carey
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-23
- **Primary completion:** 2025-03-03
- **Final completion:** 2025-03-20
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** Funding terminated
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710122, "Vancomycin for Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03710122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*